We are developing medicines to selectively eliminate senescent cells, called senolytic medicines. Our initial focus is on delivering localized therapy in osteoarthritis, ophthalmology and pulmonary disease. Beyond cellular senescence, we are uncovering additional underlying mechanisms that contribute to age-related diseases including:
Our lead product candidate, UBX0101, is designed to treat musculoskeletal disease with an initial focus on osteoarthritis. This product candidate is a potent senolytic small molecule inhibitor of the MDM2/p53 protein interaction. Disruption of this protein interaction can trigger the elimination of senescent cells. Our IND application has been cleared by the U.S. FDA, and we plan to initiate a Phase 1 clinical trial in osteoarthritis in the second quarter of 2018.
UBX1967 is our second lead product candidate for the potential treatment of ophthalmologic diseases. UBX1967 is a potent senolytic small molecule inhibitor of specific members of the Bcl-2 family of apoptosis regulatory proteins. Senescent cells utilize pro-survival mechanisms to remain viable and rely on specific Bcl-2 protein family members to persist and accumulate in tissues. We plan to submit our IND application and commence a Phase 1 clinical study in an ophthalmological indication in the second half of 2019.
Boots amp; Shoes Fraser House Loake Of Summary: This double-blind, randomized, placebo-controlled Phase 1 study is evaluating the safety, tolerability and pharmacokinetics of a single intra-articular injection of UBX0101 into the femoro-tibial joint of patients diagnosed with moderate to severe painful osteoarthritis of the knee.
Status: Recruiting patients
For patients or physicians interested in learning about eligibility criteria for the trial, please visit clincialtrials.gov.
S19747 Dorset Dorchester Charming Cottage The Dorchester Stables YO4EP